NIH 2019 R44 HL |
A Novel, Non-Cytotoxic, Epigenetic Therapeutic for Sickle Cell Disease Desimone, Joseph; Saunthararajah, Yogen / Denovotherapies, LLC |
|
NIH 2018 R44 HL |
A Novel, Non-Cytotoxic, Epigenetic Therapeutic for Sickle Cell Disease Desimone, Joseph; Saunthararajah, Yogen / Denovotherapies, LLC |
|
NIH 2017 R44 HL |
A Novel, Non-Cytotoxic, Epigenetic Therapeutic for Sickle Cell Disease Desimone, Joseph; Saunthararajah, Yogen / Denovotherapies, LLC |
$225,000 |